Literature DB >> 26084899

Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment.

Masahiro Yoshida1, Takafumi Nakao1, Mirei Horiuchi1, Hideya Ueda1, Kiyoyuki Hagihara1, Hiroshi Kanashima1, Takeshi Inoue2, Erina Sakamoto3, Manabu Hirai3, Hideo Koh4, Takahiko Nakane4, Masayuki Hino4, Takahisa Yamane1.   

Abstract

BACKGROUND: The treatment strategy for diffuse large B-cell lymphoma (DLBCL) in elderly patients is problematic. Although several researchers have reported the effectiveness of comprehensive geriatric assessment (CGA) and the futility of curative treatment in 'unfit' patients with DLBCL, these propositions are not firmly established. PATIENTS AND METHODS: We conducted a retrospective analysis using a database. Patients with DLBCL were eligible if ≧ 60 yr old. CGA stratification was performed using medical records.
RESULTS: One hundred and 35 patients were identified. Anthracycline-based chemotherapy with curative intent was performed in 115 (85%) patients. According to CGA, 82 (61%) patients were classified as 'fit'. Their 1-yr overall survival (OS) was significantly better than that of 'unfit' patients [91.3% vs. 53.8%, P < 0.001]. Patients classified as 'unfit' treated with curative intent had a significantly better 1-yr OS when compared with those receiving palliative measures [66.1% vs. 19.0%, P < 0.001].
CONCLUSIONS: CGA is an effective tool for predicting outcomes in older patients with DLBCL. The patients treated with curative intent had significantly better outcomes compared with those receiving palliation, irrespective of CGA stratification. Curative treatment should be considered even for 'unfit' patients.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  comprehensive geriatric assessment; diffuse large B-cell lymphoma; elderly

Mesh:

Substances:

Year:  2015        PMID: 26084899     DOI: 10.1111/ejh.12608

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.

Authors:  Karin Ribi; Stéphanie Rondeau; Felicitas Hitz; Ulrich Mey; Milica Enoiu; Thomas Pabst; Anastasios Stathis; Natalie Fischer; Kerri M Clough-Gorr
Journal:  Support Care Cancer       Date:  2017-04-13       Impact factor: 3.603

Review 2.  Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.

Authors:  Richard J Lin; Madhusmita Behera; Catherine S Diefenbach; Christopher R Flowers
Journal:  Blood       Date:  2017-08-16       Impact factor: 22.113

3.  A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Authors:  Çağlar Çağlayan; Jordan S Goldstein; Turgay Ayer; Ashish Rai; Christopher R Flowers
Journal:  Cancer       Date:  2019-02-01       Impact factor: 6.860

4.  Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.

Authors:  Diana Nolasco-Medina; Nancy Reynoso-Noveron; Alejandro Mohar-Betancourt; Alejandro Aviles-Salas; Osvaldo García-Perez; Myrna Candelaria
Journal:  Biomed Res Int       Date:  2016-07-10       Impact factor: 3.411

5.  Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.

Authors:  Jie-Fei Bai; Hui-Xiu Han; Ru Feng; Jiang-Tao Li; Ting Wang; Chun-Li Zhang; Hui Liu
Journal:  Oncologist       Date:  2020-06-11

Review 6.  Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma.

Authors:  Myrna Candelaria; Alfonso Dueñas-Gonzalez
Journal:  Ther Adv Hematol       Date:  2021-01-30

7.  Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma.

Authors:  Masahiro Yoshida; Yosuke Nakaya; Katsujun Shimizu; Naoko Tatsumi; Minako Tsutsumi; Hoyuri Fuseya; Mirei Horiuchi; Takuro Yoshimura; Yoshiki Hayashi; Takafumi Nakao; Takeshi Inoue; Takahisa Yamane
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

8.  A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.

Authors:  Kathrine T Isaksen; Maria Adele Mastroianni; Marit Rinde; Leiv Sindre Rusten; Dlawer Abdulla Barzenje; Lloyd Frode Ramslien; Marit Slaaen; Marianne Brenn Jerm; Erlend B Smeland; Siri Rostoft; Knut Liestøl; Marianne Brodtkorb; Harald Holte
Journal:  Blood Adv       Date:  2021-11-23

9.  Clinicopathological analysis of diffuse large B-cell lymphoma lacking surface immunoglobulin light chain restriction on flow cytometry.

Authors:  Yosuke Nakaya; Miho Sakaida; Masahiro Yoshida; Katsujun Shimizu; Naoko Yagi; Minako Tsutsumi; Takuro Yoshimura; Yoshiki Hayashi; Takafumi Nakao; Takeshi Inoue; Takahisa Yamane
Journal:  J Clin Exp Hematop       Date:  2021-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.